FibroGen is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs. The Company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor biology to generate clinical programs targeting multiple therapeutic areas. FibroGen's most advanced product candidate, roxadustat, is an oral small molecule inhibitor of HIF prolyl hydroxylases in Phase 3 clinical development for the treatment of anemia in chronic kidney disease.

FibroGen's second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis.

TypePublic
HQSan Francisco, US
Founded1993
Size (employees)364 (est)
Websitefibrogen.com
FibroGen was founded in 1993 and is headquartered in San Francisco, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

FibroGen Office Locations

FibroGen has an office in San Francisco
San Francisco, US (HQ)
409 Illinois St
Show all (1)
Report incorrect company information

FibroGen Financials and Metrics

FibroGen Revenue

FibroGen's revenue was reported to be $125.67 m in FY, 2017
USD

Revenue (Q2, 2018)

75.9 m

Net income (Q2, 2018)

(64.8 m)

EBIT (Q2, 2018)

(63.8 m)

Market capitalization (21-Sep-2018)

4.9 b

Closing stock price (21-Sep-2018)

57.8

Cash (30-Jun-2018)

643.8 m
FibroGen's current market capitalization is $4.9 b.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

180.8 m179.6 m125.7 m

Revenue growth, %

(1%)

General and administrative expense

44.4 m46 m51.8 m

R&D expense

214.1 m187.2 m196.5 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

16.3 m120.6 m19.5 m28.3 m89.3 m30.1 m26.9 m29 m31.9 m75.9 m

General and administrative expense

10.5 m9.7 m11.2 m11.4 m10.4 m11.6 m11.5 m13.4 m15.6 m30.6 m

R&D expense

50.5 m51.6 m52.1 m43.7 m52.4 m40.6 m46.7 m47 m57 m109.1 m

Operating expense total

61 m61.2 m63.3 m55.1 m62.8 m52.2 m58.3 m60.4 m72.5 m139.7 m
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

153.3 m173.8 m673.7 m

Accounts Receivable

15.4 m10.4 m8.5 m

Inventories

4 m2.9 m

Current Assets

200.6 m266.5 m749 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

128.4 m236.5 m208.7 m141 m190.4 m198.3 m170.6 m290.3 m659 m643.8 m

Accounts Receivable

7 m12.2 m7.4 m5.9 m18.1 m7.7 m7.2 m8.9 m10 m30.2 m

Current Assets

155.4 m263.6 m232.6 m184 m252.3 m253.5 m256.6 m371.3 m717.2 m720.1 m

PP&E

131.7 m130.5 m129.6 m127.6 m126.3 m124.8 m122.8 m122.6 m129.9 m128.8 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(85.8 m)(61.7 m)(126.2 m)

Depreciation and Amortization

5.7 m6 m6.1 m

Inventories

978 k1.1 m

Accounts Payable

2 m(298 k)(714 k)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(46.4 m)10.7 m(34.4 m)(27.8 m)(3.5 m)(27.7 m)(33.2 m)(66.3 m)(41.4 m)(64.8 m)

Depreciation and Amortization

2.8 m4.2 m1.5 m3 m4.5 m1.5 m3.1 m1.5 m3.1 m

Accounts Payable

2.4 m(636 k)(317 k)(5 m)(3 m)(4.5 m)(3.3 m)(3 m)(2 m)(2.3 m)

Cash From Operating Activities

58.9 m20.7 m(17.3 m)27.4 m25.7 m(27.1 m)(46.9 m)(32 m)(66.9 m)
USDY, 2018

Financial Leverage

1.8 x
Show all financial metrics

FibroGen Operating Metrics

FY, 2016

Facilities

2

Patent Portfolios

4

Phase II Trials Products

1

Phase III Trials Products

1
Show all operating metrics

FibroGen Revenue Breakdown

Embed Graph

FibroGen revenue breakdown by geographic segment: 85.6% from Europe, 14.4% from Japan and 0.1% from Other

Report incorrect company information

FibroGen News and Updates

FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

SAN FRANCISCO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with id…

FibroGen Reports Second Quarter 2018 Financial Results

Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018

FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018

Conference Call and Audio Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT) Conference Call and Audio Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT)
Show more
Report incorrect company information

FibroGen Company Life and Culture

Report incorrect company information